Skip to main content

Table 3 Changes in eGFR value according to renal function decrease

From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Observation period, months Group D Group ND
Number of patients Absolute value, (mL/min/1.73 m2) Changed value, (mL/min/1.73 m2) p-value Number of patients Absolute value, (mL/min/1.73 m2) Changed value, (mL/min/1.73 m2) p-value
0 13 83.9 ± 16.2 27 69.6 ± 17.0
1 13 71.9 ± 20.9 −12.0 ± 11.4 0.0033 27 63.5 ± 2.9 −5.3 ± 12.6 0.0403
3 13 74.2 ± 19.9 −9.6 ± 9.9 0.0057 27 67.1 ± 16.1 −2.8 ± 10.6 0.1874
6 13 71.0 ± 22.3 −12.9 ± 8.9 0.0003 27 67.9 ± 17.2 −2.1 ± 11.7 0.3697
12 13 70.3 ± 18.7 −13.5 ± 7.1 < 0.0001 25 71.2 ± 21.9 0.1 ± 11.4 0.9605
18 13 72.5 ± 25.4 −11.4 ± 15.9 0.0295 19 68.8 ± 19.1 −0.47 ± 10.6 0.8533
24 12 66.6 ± 25.5 −18.3 ± 17.6 0.0009 15 66.6 ± 15.3 −5.93 ± 10.7 0.0571
30 11 59.8 ± 22.0 −25.6 ± 11.0 < 0.0001 10 65.8 ± 18.1 −8.5 ± 12.9 0.0791
36 7 54.9 ± 16.6 −28.5 ± 9.4 0.0003 8 67.1 ± 19.6 −9.4 ± 9.5 0.0346
42 7 52.3 ± 13.5 −31.1 ± 10.9 0.0004 8 68.4 ± 17.3 −8.1 ± 7.6 0.0252
48 6 52.3 ± 15.3 −29.0 ± 11.0 0.0020 6 66.7 ± 12.6 −11.5 ± 5.4 0.0136
54 3 46.3 ± 6.4 −25.0 ± 1.7 0.0022 3 88.4 ± 34.6 0.9 ± 11.9 0.9276
60 1 48.6 −23.4 n.c. 2 97.6 ± 20.4 −6.3 ± 5.2 0.4393
  1. n.c. not calculated